S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898066|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : March 6, 2015
RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease.
PURPOSE: This laboratory study is analyzing chromosomes in patients with newly diagnosed multiple myeloma or other blood disease.
|Condition or disease||Intervention/treatment|
|Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Precancerous/Nonmalignant Condition||Genetic: cytogenetic analysis Genetic: fluorescence in situ hybridization|
- Compare the frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics in patients with newly diagnosed multiple myeloma (MM) or other monoclonal gammopathies (MG).
- Examine the prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival in these patients.
- Compare the prognostic value of cytogenetics and FISH with other MM and MG prognostic factors in these patients.
- Correlate the presence of cytogenetic and FISH features with clinical pathophysiological, cellular, or other molecular characteristics in these patients.
OUTLINE: Patients receive treatment as directed by the treatment clinical trial on which they are registered. Patients undergo bone marrow or blood sample collection periodically for conventional cytogenetic analysis and fluorescence in situ hybridization studies (FISH). Samples are analyzed for deleted 13q/monosomy 13 and chromosomal abnormalities.
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||37 participants|
|Official Title:||Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||June 2007|
Genetic: cytogenetic analysis
- Frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics [ Time Frame: 1 year ]
- Prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival [ Time Frame: 1 year ]
- Comparison of prognostic value of cytogenetics and FISH with other multiple myeloma and monoclonal gammopathy prognostic factors [ Time Frame: 1 year ]
- Correlation between the presence of cytogenetic and FISH features and clinical pathophysiological, cellular, or other molecular characteristics [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898066
|Study Chair:||Diane L. Persons, MD||University of Kansas|